Pfizer Announces Results from XELJANZ XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with a JAK Inhibitor
NEW YORK--(BUSINESS WIRE)--Jun 12, 2019--
NEW YORK--(BUSINESS WIRE)--Jun 12, 2019--